- Home
- REGN vs JD Comparison
REGN vs JD Comparison
Compare REGN & JD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- JD
- Stock Information
- Founded
- REGN 1988
- JD 2006
- Country
- REGN United States
- JD China
- Employees
- REGN N/A
- JD N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- JD Other Specialty Stores
- Sector
- REGN Health Care
- JD Consumer Discretionary
- Exchange
- REGN Nasdaq
- JD Nasdaq
- Market Cap
- REGN 59.5B
- JD 48.9B
- IPO Year
- REGN 1991
- JD 2014
- Fundamental
- Price
- REGN $576.66
- JD $33.15
- Analyst Decision
- REGN Buy
- JD Buy
- Analyst Count
- REGN 23
- JD 12
- Target Price
- REGN $795.04
- JD $43.17
- AVG Volume (30 Days)
- REGN 1.2M
- JD 20.5M
- Earning Date
- REGN 10-28-2025
- JD 11-13-2025
- Dividend Yield
- REGN 0.61%
- JD 3.02%
- EPS Growth
- REGN 5.03
- JD 29.31
- EPS
- REGN 39.67
- JD 3.57
- Revenue
- REGN $14,214,200,000.00
- JD $176,598,313,733.00
- Revenue This Year
- REGN N/A
- JD $15.12
- Revenue Next Year
- REGN $4.74
- JD $5.71
- P/E Ratio
- REGN $14.53
- JD $9.28
- Revenue Growth
- REGN 5.38
- JD 14.47
- 52 Week Low
- REGN $476.49
- JD $29.90
- 52 Week High
- REGN $1,024.36
- JD $46.45
- Technical
- Relative Strength Index (RSI)
- REGN 51.13
- JD 47.06
- Support Level
- REGN $541.00
- JD $32.18
- Resistance Level
- REGN $577.17
- JD $36.14
- Average True Range (ATR)
- REGN 19.79
- JD 1.13
- MACD
- REGN -1.32
- JD -0.39
- Stochastic Oscillator
- REGN 46.31
- JD 32.58
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About JD JD.com Inc.
JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.